CO6331447A2 - Composiciones intranasales que comprenden un descongestionante y un corticoesteroide - Google Patents

Composiciones intranasales que comprenden un descongestionante y un corticoesteroide

Info

Publication number
CO6331447A2
CO6331447A2 CO11004272A CO11004272A CO6331447A2 CO 6331447 A2 CO6331447 A2 CO 6331447A2 CO 11004272 A CO11004272 A CO 11004272A CO 11004272 A CO11004272 A CO 11004272A CO 6331447 A2 CO6331447 A2 CO 6331447A2
Authority
CO
Colombia
Prior art keywords
nasal
symptoms
allergic
itching
treatment
Prior art date
Application number
CO11004272A
Other languages
English (en)
Spanish (es)
Inventor
Melvyn Danzig
Ariel Teper
Davis F Gates
Heribert W Staudinger
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CO6331447A2 publication Critical patent/CO6331447A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO11004272A 2008-07-15 2011-01-17 Composiciones intranasales que comprenden un descongestionante y un corticoesteroide CO6331447A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8099008P 2008-07-15 2008-07-15
US11672108P 2008-11-21 2008-11-21

Publications (1)

Publication Number Publication Date
CO6331447A2 true CO6331447A2 (es) 2011-10-20

Family

ID=41259574

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11004272A CO6331447A2 (es) 2008-07-15 2011-01-17 Composiciones intranasales que comprenden un descongestionante y un corticoesteroide

Country Status (13)

Country Link
US (1) US20110189106A1 (enExample)
EP (1) EP2318049A1 (enExample)
JP (1) JP2011528355A (enExample)
KR (1) KR20110045004A (enExample)
CN (1) CN102159244A (enExample)
AR (1) AR072805A1 (enExample)
AU (1) AU2009271162A1 (enExample)
CA (1) CA2730590A1 (enExample)
CO (1) CO6331447A2 (enExample)
MX (1) MX2011000590A (enExample)
RU (1) RU2011101151A (enExample)
TW (1) TW201016209A (enExample)
WO (1) WO2010009028A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2739353A1 (en) * 2008-10-10 2010-04-15 Schering Corporation Corticosteroid compositions and methods of treatments thereof
CA2841644A1 (en) * 2011-08-02 2013-02-07 Cipla Limited Pharmaceutical composition comprising ebastine and fluticasone
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
CN105473133A (zh) 2013-04-30 2016-04-06 欧缇托匹克公司 干粉制剂及使用方法
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
MX2015009429A (es) * 2013-10-04 2015-10-09 Glenmark Pharmaceuticals Ltd Tratamiento de rinitis alergica utilizando una combinacion de mometasona y olopatadina.
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
JP6945614B2 (ja) * 2014-03-26 2021-10-06 オプティノーズ アズ 経鼻投与
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
CN106692115A (zh) * 2015-11-13 2017-05-24 天津金耀集团有限公司 一种环索奈德混悬鼻喷剂组合物
CA3076353A1 (en) 2017-09-22 2019-03-28 Otitopic Inc. Dry powder compositions with magnesium stearate
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
CN112006987B (zh) * 2019-12-13 2023-04-28 吉林省健敷鼻科技有限公司 一种治疗鼻炎的冷敷凝胶及其之制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003272450A1 (en) * 2002-09-13 2004-04-30 C. Steven Smith Novel composition and method for treatment of upper respiratory conditions
US20040191176A1 (en) * 2003-03-28 2004-09-30 Kaplan Leonard W Formulations for treatment of pulmonary disorders
US20040235807A1 (en) * 2003-05-21 2004-11-25 Weinrich Karl P. Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
US7902177B2 (en) * 2005-05-02 2011-03-08 Wandzel Richard A Treatment of congestion using steroids and adrenergics
US20100099650A1 (en) * 2006-10-10 2010-04-22 Knauer Kent A Nasal spray composition and method for treating rhinitis, sinusitis or both

Also Published As

Publication number Publication date
MX2011000590A (es) 2011-03-01
JP2011528355A (ja) 2011-11-17
AR072805A1 (es) 2010-09-22
RU2011101151A (ru) 2012-07-20
CA2730590A1 (en) 2010-01-21
EP2318049A1 (en) 2011-05-11
CN102159244A (zh) 2011-08-17
TW201016209A (en) 2010-05-01
WO2010009028A1 (en) 2010-01-21
AU2009271162A1 (en) 2010-01-21
US20110189106A1 (en) 2011-08-04
KR20110045004A (ko) 2011-05-03

Similar Documents

Publication Publication Date Title
AR072805A1 (es) Composiciones intranasales formas galenicas y metodos de tratamiento.
EA201101576A1 (ru) Лекарственная форма токотриенол хинонов для лечения офтальмических (глазных) заболеваний
EA201201465A1 (ru) Лекарственные формы хинонов для лечения офтальмических заболеваний
IN2015DN04311A (enExample)
JOP20200260B1 (ar) مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
AR066016A1 (es) Uso de un inhibidor del tnf alfa junto con una antihistamina para tratar la rinitis alergica y la conjuntivitis alergica
MX2007011772A (es) Formulaciones de antihistaminico y corticosteroide de materia en nanoparticulas.
PH12014501491A1 (en) Subcutaneous therapeutic use of dpp-4 inhibitor
WO2009142772A3 (en) Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
CR20190331A (es) UNA FORMA CRISTALINA A DE UN MODULADOR DEL RECEPTOR ANDROGÉNICO (Divisional 2014-0549)
MX2015008187A (es) Inhibidores de alk deuterados.
ES2675779T3 (es) Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R
CL2015001241A1 (es) Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13)
MX385122B (es) Uso de ibrutinib en el tramiento de enfermedad injerto contra huésped crónica.
BR112015018438A2 (pt) anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
CO6630082A2 (es) Tratamiento de lupus nefritis usando laquinimod
MX360857B (es) Régimen de dosificación para inhibidores de janus quinasa (jak).
NZ704247A (en) Compositions and treatment for eye diseases and disorders
MX2016002866A (es) Composiciones para comprimidos bucodispersables que contienen corticosteroides para esofagitis eosinofilica.
PE20140750A1 (es) Tratamiento del mieloma multiple
PH12013500857A1 (en) Methods and compositions for treating hiv-associated diarrhea
MX357746B (es) Uso de células t de memoria central anti-tercera parte para el tratamiento anti-leucemia/linfoma.
BR112015004469A2 (pt) sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares

Legal Events

Date Code Title Description
FC Application refused